Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 12
Submit an article Journal homepage
127
Views
2
CrossRef citations to date
0
Altmetric
Review

Pharmacotherapy of lupus nephritis: time for a consensus?

Garyfallia Perysinaki Rethymnon General Hospital, Division of Nephrology, Rethymnon, Greece
,
Simeon Panagiotakis University of Crete, Medical School, Internal Medicine, and Rheumatology, Clinical Immunology, and Allergy, Voutes 71500, Heraklion, PO Box 2209, Greece +30 2810 394635; +30 2810 392024; [email protected]
,
George Bertsias University of Crete, Medical School, Internal Medicine, and Rheumatology, Clinical Immunology, and Allergy, Voutes 71500, Heraklion, PO Box 2209, Greece +30 2810 394635; +30 2810 392024; [email protected]
&
Dimitrios T Boumpas University of Crete, Medical School, Internal Medicine, and Rheumatology, Clinical Immunology, and Allergy, Voutes 71500, Heraklion, PO Box 2209, Greece +30 2810 394635; +30 2810 392024; [email protected]
Pages 2099-2115 | Published online: 31 Jul 2008

Bibliography

  • Weening JJ, D'agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited Kidney Int 2004;65:521-30
  • Mok CC, Wong RW, Lai KN. Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis 2003;62:799-804
  • Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy long-term follow-up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002
  • Sidiropoulos PI, Kritikos HD, Boumpas DT. Lupus nephritis flares. Lupus 2005;14:49-52
  • Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10:413-24
  • Renal Disease Subcommittee Of The American College Of Rheumatology Ad Hoc Committee On Systemic Lupus Erythematosus Response Criteria: The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;54:421-32
  • Dooley MA, Hogan S, Jennett C, et al. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997;51:1188-95
  • Tektonidou MG, Sotsiou F, Nakopoulou L, et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 2004;50:2569-79
  • Petri M. Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am 2000;2:199-213
  • Manger K, Manger B, Repp R, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002;61:1065-70
  • Austin HA 3rd, Boumpas DT, Vaughan EM, et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994;45:544-50
  • Boumpas DT, Sidiropoulos P, Bertsias G. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? Nat Clin Pract Rheumatol 2005;1:22-30
  • Mak A, Mok CC, Chu WP, et al. Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus 2007;16:28-34
  • Ponticelli C. Current treatment recommendations for lupus nephritis. Drugs 1990;40:19-30
  • Boumpas DT, Austin III HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5
  • Illei GG, Austin HA III, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57
  • Gourley MF, Austin HA III, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549-57
  • Grootscholten C, Bajema IM, Florquin S, et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007;56:924-37
  • Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006;70:732-42
  • Donadio JV Jr, Holley KE, Ferguson RH, et al. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978;299:1151-5
  • Balow JE, Austin HA III, Muenz LR, et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984;311:491-5
  • Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9
  • Chan TM, Tse KC, Tang CS, et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005;14:265-72
  • Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119:355
  • Houssiau FA, Vasconcelos C, Cruz DD, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31
  • Houssiau FA, Vasconcelos C, Cruz DD, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-40
  • Frutos MA, Gómez AM, Ramón E, et al. Intravenous cyclophosphamide for lupus nephritis: twenty years reducing the dose. Nefrología 2007;27:12-22
  • Seong SS, Choi CB, Yun HR, et al. Effect of lower dose intravenous cyclophosphamide on remission induction in Korean patients with lupus nephritis. Rheumatol Int 2008;28:453-8
  • Pavletic SZ, Llei GG. The role of immune ablation and stem cell transplantation in severe SLE. Best Pract Res Clin Rheumatol 2005;19:839-58
  • Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006;295:527-35
  • Petri M, Brodsky R. High-dose cyclophosphamide and stem cell transplantation for refractory systemic lupus erythematosus. JAMA 2006;295:559-60
  • Chan TM, Li FK, Hao WK, et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999;8:545-55
  • Sloan RP, Schwartz MM, Korbet SM, et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996;7:299-305
  • Austin H, Vaughn EM, Balow JE, et al. Lupus membranous nephropathy: controlled trial of prednisone, pulse cyclophosphamide and cyclosporine [abstract]. AJ Am Soc Nephrol 2004;15:54A
  • Boumpas DT, Austin HA III, Vaughn EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-9
  • Mok CC, Lau CS, Wong RWS. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998;41:831-7
  • Haubitz M, Ehlerding C, Kamino K, et al. Reduced gonadal toxicity after IV cyclophosphamide administration in patients with nonmalignant diseases. Clin Nephrol 1998;29:19-23
  • Somers EC, Marder W, Christman GM, et al. Use of a gonadotropin-releasing hormone analogue for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761-7
  • Masala A, Faedda R, Alagna S, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 1997;126:292-5
  • Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62
  • Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005;10:504-10
  • Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84
  • Hu W, Liu Z, Shen, S, et al. Mycophenolate mofetil vs cyclophosphamide therapy for diffuse proliferative lupus nephritis Chin Med J (England) 2002;115:705-9
  • Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28
  • Burchardi C, Schlöndorff D. Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide. Nat Clin Pract Nephrol 2006;2:314-5
  • Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006;8:R182
  • Walsh M, James M, Jayne D, et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007;2:968-75
  • Ginzler EM, Appel GB, Dooley MA, et al. Mycophenolate mofetil and intravenous cyclophosphamide in the Aspreva Lupus Management Study (ALMS): efficacy by racial group. Arthritis American College of Rheumatology Meeting; Boston, USA; 6 - 11 November 2007
  • Mok CC. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum 2006;36:71-81
  • Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80
  • Kapitsinou PP, Boletis JN, Skopouli FN, et al. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 2004;43:377-80
  • Karim MY, Pisoni CN, Ferro L, et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 2005;44:1317-21
  • Spetie DN, Tang Y, Rovin BH, et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 2004;66:2411-5
  • Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone alone. Arthritis Rheum 1991;34:945-50
  • Benenson E, Fries JWU, Heilig B, et al. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin Rheumatol 2005;24:251-7
  • Nossent HC, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology (Oxford) 2000;39:969-74
  • Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006;1:925-32
  • Manger K, Kalden JR, Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1996;35:669-75
  • Caccavo D, Lagana B, Miiterhofer AP, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 1997;40:27-35
  • Ogawa H, Kameda H, Nagasawa H, et al. Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Mod Rheumatol 2007;17:92-7
  • Hu W, Liu Z, Shen S, et al. Cyclosporine A in treatment of membranous lupus nephropathy. Chin Med J (England) 2003;116:1827-30
  • Dostal C, Tesar V, Rychlik I, et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 1998;7:29-36
  • Ferrario L, Bellone M, Bozzolo E, et al. Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporine A. Rheumatology (Oxford) 2000;39:218-20
  • Maruyama M, Yamasaki Y, Sada K, et al. Good response of membranous lupus nephritis to tacrolimus. Clin Nephrol 2006;65:276-9
  • Mok CC, Tong KH, To CH, et al. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005;68:813-7
  • Tanaka H, Oki E, Tsugawa K, et al. Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study. Lupus 2007;16:896
  • Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenilate Mofetil (MMF) in Lupus Nephritis (III/IV/V). Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00298506 [Accessed on 6 June 2008]
  • To Compare the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis. Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00371319 [Accessed on 6 June 2008]
  • A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis. Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00404794 [Accessed on 6 June 2008]
  • Walsh M, Jayne D. Rituximab in the treatment of anti-neutrophilcytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future Kidney Int 2007;72:676-82
  • Fra GP, Avanzi GC, Bartol E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003;12:783-7
  • Van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E, et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004;33:423-7
  • Jacobson SH, Van Vollenhoven RF, Gunnarsson I. Rituximab-induced long-term remission of membranous lupus nephritis. Nephrol Dial Transplant 2006;21:1742-3
  • Carroll RP, Brown F, Kerr PG. Anti-CD20 antibody treatment in refractory class IV lupus nephritis. Nephrol Dial Transplant 2007;22:291-3
  • Looney J, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9
  • Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005;44:1542-5
  • Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20
  • Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52:501-3
  • Smith KGC, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-82
  • Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006;8:R83
  • Boren EJ, Cheema GS, Naguwa M, et al. The emergence of progresssive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008;30:90-8
  • Genetech: Newsroom: Press releases: News Release 29 May 2008. Available from: http://www.gene.com/gene/news[Accessed on 6 June 2008]
  • A Study to Evaluate the Efficacy and Safety of Rituximab in Patients With Severe Systemic Lupus Erythematosus (EXPLORER). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00137969?term=EXPLORER&rank=2 [Accessed on 6 June 2008]
  • A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis (LUNAR). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00282347? term=LUNAR&rank=2 [Accessed on 6 June 2008]
  • Micheloud D, Nuno L, Rodríguez-Mahou M, et al. Efficacy and safety of etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy. Lupus 2006;15:881-5
  • Euler HH, Schroeder JO, Harten P, et al. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994;37:1784
  • Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992;326:1373
  • Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum 1998;41:414
  • Smith JW, Weinstein R, Hillyer. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion 2003;43:820
  • Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87
  • MacKinnon M, Shurraw S, Akbari A, et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006;48:8-20
  • Moroni G, Quaglini S, Gallelli B, et al. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007;22:2531-9
  • Teplitsky V, Shoenfeld Y, Tanay A. The renin–angiotensin system in lupus: physiology, genes and practice, in animals and humans. Lupus 2006;15:319-25
  • Kandal H, Kubo K, Tateishi S, et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 2005;14:288-92
  • Austin HA, Illei GG. Membranous lupus nephritis. Lupus 2005;14:65-71
  • Bertsias GK, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erytematosus (SLE): report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2008;67:195-205
  • Jadoul M. Optimal care of lupus nephritis patients. Lupus 2005;14:72-6
  • Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003;48:3159-67
  • Nikpour M, Urowitz MB, Gladman DD. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2005;31:329-54, vii-viii
  • McCarey D, McInnes B, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo controlled trial. Lancet 2004;363:2015-21
  • Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 2002;17:798-802
  • Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004;109:II42-8
  • Voulgarelis M, Kokori SIG, Ioannidis JPA, et al. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin. Ann Rheum Dis 2000;59:217-22
  • Schett G, Fibras U, Fureder W, et al. Decreased serum erythropoietin and its relation to anti-erythropoetin antibodies in anaemia of systemic lupus erythematosus. Rheumatology (Oxford) 2001;40:424-31
  • Hebert LA, Birmingham DJ, Shen XP, et al. Effect of recombinant erythropoietin therapy on autoimmunity in systemic lupus erythematosus. Am J Kidney Dis 1994;24:25-32
  • Kiss E, Kávai M, Csipõ I, et al. Recombinant human erythropoietin modulates erythrocyte complement receptor 1 functional activity in patients with lupus nephritis. Clin Nephrol 1998;49:364-9
  • Giannouli S, Voulgarelis M, Ziakas PD, et al. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis 2006;65:144-8
  • The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI ™). Available from: http://www.kdoqi.org [Accessed on 6 June 2008]
  • McDonald SP, Russ GR. Survival of recipients of cadaveric kidney transplants compared with those receiving dialysis treatment in Australia and New Zealand, 1991 – 2001. Nephrol Dial Transplant 2002;17:2212-9
  • Bunnapradist S, Chung P, Peng A, et al. Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procurement and Transplantation Network Database. Transplantation 2006;82:612-8
  • Stone JH, Amend WJC, Criswell LA. Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls. Arthritis Rheum 1998;41:1438-45
  • Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000;136(2):243-7
  • Askenazi D, Myones B, Kamdar A, et al. Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy. Pediatr Nephrol 2007;22:981-6
  • Wang LC, Yang YH, Lu MY, et al. Retrospective analysis of the renal outcome of pediatric lupus nephritis. Clin Rheumatol 2004;23:318-23
  • Barbano G, Gusmano R, Damasio B, et al. Childhood-onset lupus nephritis: a single-center experience of pulse intravenous cyclophosphamide therapy. J Nephrol 2002;15(2):123-9
  • Adams A, MacDermott EJ, Lehman TJA. Pharmacotherapy of lupus nephritis in children: a recommended treatment approach. Drugs 2006;66(9):1191-207
  • Lee BS, Cho HY, Kim EJ, et al. Clinical outcomes of childhood lupus nephritis: a single center's experience. Pediatr Nephrol 2007;22:222-31
  • Baca V, Catalán T, Villasís-Keever M, et al. Effect of low-dose cyclosporine A in the treatment of refractory proteinuria in childhood – onset lupus nephritis. Lupus 2006;15:490-5
  • Fu LW, Yang LY, Chen WP, et al. Clinical efficacy of cyclosporin A neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatol 1998;37:217-21
  • Lehman TJA, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis 2004;63:321-3
  • Buratti S, Szer IS, Spencer CH, et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001;28:2103-8
  • Nwobi O, Abitbol CL, Chandar J, et al. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 2008;23:413-9
  • Willems M, Haddad E, Niaudet P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148:623-7
  • Tanaka H, Tsugawa K, Oki E, et al. Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin Rheumatol 2008;27:85-9
  • Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005;52:3168-74
  • Jones DC, Hayslett JC. Outcome of pregnancy in women with moderate or severe renal insufficiency. N Engl J Med 1996;335:226-32
  • Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
  • Tandon A, Ibanez D, Gladman DD, et al. The effect of pregnancy on lupus nephritis. Arthritis Rheum 2004;50:3941-6
  • Carmona F, Font J, Moga I, et al. Class III – IV proliferative lupus nephritis and pregnancy: a study of 42 cases. Am J Reprod Immunol 2005;53:182-8
  • MoRoni G, Quaglini S, Banfi G, et al. Pregnancy in lupus nephritis. Am J Kidney Dis 2002;40(4):713-20
  • Khamashta MA. Systemic lupus erythematosus and pregnancy. Best Pract Res Clin Rheumatol 2006;20:685-94
  • Cochat P, Decramer S, Robert-Gnansia E, et al. Renal outcome of children exposed to cyclosporine in utero. Transplant Proc 2004;36(Suppl 2S):208S-210S
  • Tincani A, Nuzzo M, Lojacono A, et al. Contraception in adolescents with systemic lupus erythematosus. Lupus 2007;16:600-5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.